Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 110 entries
Sorted by: Best Match Show Resources per page
A scalable, clinically severe pig model for Duchenne muscular dystrophy.

Disease models & mechanisms

Stirm M, Fonteyne LM, Shashikadze B, Lindner M, Chirivi M, Lange A, Kaufhold C, Mayer C, Medugorac I, Kessler B, Kurome M, Zakhartchenko V, Hinrichs A, Kemter E, Krause S, Wanke R, Arnold GJ, Wess G, Nagashima H, Hrabĕ de Angelis M, Flenkenthaler F, Kobelke LA, Bearzi C, Rizzi R, Bähr A, Reese S, Matiasek K, Walter MC, Kupatt C, Ziegler S, Bartenstein P, Fröhlich T, Klymiuk N, Blutke A, Wolf E.
PMID: 34796900
Dis Model Mech. 2021 Dec 01;14(12). doi: 10.1242/dmm.049285. Epub 2021 Dec 16.

Large-animal models for Duchenne muscular dystrophy (DMD) are crucial for the evaluation of diagnostic procedures and treatment strategies. Pigs cloned from male cells lacking DMD exon 52 (DMDΔ52) exhibit molecular, clinical and pathological hallmarks of DMD, but die before...

Cite
Stirm M, Fonteyne LM, Shashikadze B, et al. A scalable, clinically severe pig model for Duchenne muscular dystrophy. Dis Model Mech. 2021;14(12)doi: 10.1242/dmm.049285.
Stirm, M., Fonteyne, L. M., Shashikadze, B., Lindner, M., Chirivi, M., Lange, A., Kaufhold, C., Mayer, C., Medugorac, I., Kessler, B., Kurome, M., Zakhartchenko, V., Hinrichs, A., Kemter, E., Krause, S., Wanke, R., Arnold, G. J., Wess, G., Nagashima, H., Hrabĕ de Angelis, M., Flenkenthaler, F., Kobelke, L. A., Bearzi, C., Rizzi, R., Bähr, A., Reese, S., Matiasek, K., Walter, M. C., Kupatt, C., Ziegler, S., Bartenstein, P., Fröhlich, T., Klymiuk, N., Blutke, A., & Wolf, E. (2021). A scalable, clinically severe pig model for Duchenne muscular dystrophy. Disease models & mechanisms, 14(12), . https://doi.org/10.1242/dmm.049285
Stirm, Michael, et al. "A scalable, clinically severe pig model for Duchenne muscular dystrophy." Disease models & mechanisms vol. 14,12 (2021). doi: https://doi.org/10.1242/dmm.049285
Stirm M, Fonteyne LM, Shashikadze B, Lindner M, Chirivi M, Lange A, Kaufhold C, Mayer C, Medugorac I, Kessler B, Kurome M, Zakhartchenko V, Hinrichs A, Kemter E, Krause S, Wanke R, Arnold GJ, Wess G, Nagashima H, Hrabĕ de Angelis M, Flenkenthaler F, Kobelke LA, Bearzi C, Rizzi R, Bähr A, Reese S, Matiasek K, Walter MC, Kupatt C, Ziegler S, Bartenstein P, Fröhlich T, Klymiuk N, Blutke A, Wolf E. A scalable, clinically severe pig model for Duchenne muscular dystrophy. Dis Model Mech. 2021 Dec 01;14(12). doi: 10.1242/dmm.049285. Epub 2021 Dec 16. PMID: 34796900; PMCID: PMC8688409.
Copy Download .nbib Format: NLM
Enrichment of Glial Cells From Human Post-mortem Tissue for Transcriptome and Proteome Analysis Using Immunopanning.

Frontiers in cellular neuroscience

Nolle A, van Dijken I, Waelti CM, Calini D, Bryois J, Lezan E, Golling S, Augustin A, Foo L, Hoozemans JJM.
PMID: 34966261
Front Cell Neurosci. 2021 Dec 13;15:772011. doi: 10.3389/fncel.2021.772011. eCollection 2021.

Glia cells have a crucial role in the central nervous system and are involved in the majority of neurological diseases. While glia isolation techniques are well established for rodent brain, only recent advances in isolating glial cells from human...

Cite
Nolle A, van Dijken I, Waelti CM, et al. Enrichment of Glial Cells From Human Post-mortem Tissue for Transcriptome and Proteome Analysis Using Immunopanning. Front Cell Neurosci. 2021;15:772011doi: 10.3389/fncel.2021.772011.
Nolle, A., van Dijken, I., Waelti, C. M., Calini, D., Bryois, J., Lezan, E., Golling, S., Augustin, A., Foo, L., & Hoozemans, J. J. M. (2021). Enrichment of Glial Cells From Human Post-mortem Tissue for Transcriptome and Proteome Analysis Using Immunopanning. Frontiers in cellular neuroscience, 15772011. https://doi.org/10.3389/fncel.2021.772011
Nolle, Anna, et al. "Enrichment of Glial Cells From Human Post-mortem Tissue for Transcriptome and Proteome Analysis Using Immunopanning." Frontiers in cellular neuroscience vol. 15 (2021): 772011. doi: https://doi.org/10.3389/fncel.2021.772011
Nolle A, van Dijken I, Waelti CM, Calini D, Bryois J, Lezan E, Golling S, Augustin A, Foo L, Hoozemans JJM. Enrichment of Glial Cells From Human Post-mortem Tissue for Transcriptome and Proteome Analysis Using Immunopanning. Front Cell Neurosci. 2021 Dec 13;15:772011. doi: 10.3389/fncel.2021.772011. eCollection 2021. PMID: 34966261; PMCID: PMC8711556.
Copy Download .nbib Format: NLM
High-grade astrocytoma with piloid features (HGAP): the Charité experience with a new central nervous system tumor entity.

Journal of neuro-oncology

Bender K, Perez E, Chirica M, Onken J, Kahn J, Brenner W, Ehret F, Euskirchen P, Koch A, Capper D, Kaul D.
PMID: 33905054
J Neurooncol. 2021 May;153(1):109-120. doi: 10.1007/s11060-021-03749-z. Epub 2021 Apr 27.

PURPOSE: High-grade astrocytoma with piloid features (HGAP) is a recently described brain tumor entity defined by a specific DNA methylation profile. HGAP has been proposed to be integrated in the upcoming World Health Organization classification of central nervous system...

Cite
Bender K, Perez E, Chirica M, et al. High-grade astrocytoma with piloid features (HGAP): the Charité experience with a new central nervous system tumor entity. J Neurooncol. 2021;153(1):109-120doi: 10.1007/s11060-021-03749-z.
Bender, K., Perez, E., Chirica, M., Onken, J., Kahn, J., Brenner, W., Ehret, F., Euskirchen, P., Koch, A., Capper, D., & Kaul, D. (2021). High-grade astrocytoma with piloid features (HGAP): the Charité experience with a new central nervous system tumor entity. Journal of neuro-oncology, 153(1), 109-120. https://doi.org/10.1007/s11060-021-03749-z
Bender, Katja, et al. "High-grade astrocytoma with piloid features (HGAP): the Charité experience with a new central nervous system tumor entity." Journal of neuro-oncology vol. 153,1 (2021): 109-120. doi: https://doi.org/10.1007/s11060-021-03749-z
Bender K, Perez E, Chirica M, Onken J, Kahn J, Brenner W, Ehret F, Euskirchen P, Koch A, Capper D, Kaul D. High-grade astrocytoma with piloid features (HGAP): the Charité experience with a new central nervous system tumor entity. J Neurooncol. 2021 May;153(1):109-120. doi: 10.1007/s11060-021-03749-z. Epub 2021 Apr 27. PMID: 33905054; PMCID: PMC8131327.
Copy Download .nbib Format: NLM
Extra-articular involvement of rheumatoid arthritis in three seropositive patients in the absence of initial joint involvement.

Immunity, inflammation and disease

Chirila RM, Berianu F, Abril A, Butendieck RR.
PMID: 34473908
Immun Inflamm Dis. 2021 Dec;9(4):1613-1617. doi: 10.1002/iid3.514. Epub 2021 Sep 02.

INTRODUCTION: Extra-articular involvement (EAI) in rheumatoid arthritis (RA) is rare, severe and usually presents after years of joint involvement. Onset of RA as lung involvement has been published. We describe a series of three patients with strongly positive anti-citrullinated...

Cite
Chirila RM, Berianu F, Abril A, et al. Extra-articular involvement of rheumatoid arthritis in three seropositive patients in the absence of initial joint involvement. Immun Inflamm Dis. 2021;9(4):1613-1617doi: 10.1002/iid3.514.
Chirila, R. M., Berianu, F., Abril, A., & Butendieck, R. R. (2021). Extra-articular involvement of rheumatoid arthritis in three seropositive patients in the absence of initial joint involvement. Immunity, inflammation and disease, 9(4), 1613-1617. https://doi.org/10.1002/iid3.514
Chirila, Razvan M, et al. "Extra-articular involvement of rheumatoid arthritis in three seropositive patients in the absence of initial joint involvement." Immunity, inflammation and disease vol. 9,4 (2021): 1613-1617. doi: https://doi.org/10.1002/iid3.514
Chirila RM, Berianu F, Abril A, Butendieck RR. Extra-articular involvement of rheumatoid arthritis in three seropositive patients in the absence of initial joint involvement. Immun Inflamm Dis. 2021 Dec;9(4):1613-1617. doi: 10.1002/iid3.514. Epub 2021 Sep 02. PMID: 34473908; PMCID: PMC8589363.
Copy Download .nbib Format: NLM
Sigma 1 Receptor is Overexpressed in Hepatocellular Adenoma: Involvement of ERα and HNF1α.

Cancers

Villemain L, Prigent S, Abou-Lovergne A, Pelletier L, Chiral M, Pontoglio M, Foufelle F, Caruso S, Pineau R, Rebouissou S, Chevet E, Zucman-Rossi J, Combettes L.
PMID: 32784704
Cancers (Basel). 2020 Aug 07;12(8). doi: 10.3390/cancers12082213.

Sigma receptor 1 (SigR1) is an endoplasmic reticulum resident integral membrane protein whose functions remain unclear. Although the liver shows the highest expression of SigR1, its role in this organ is unknown. SigR1 is overexpressed in many cancers and...

Cite
Villemain L, Prigent S, Abou-Lovergne A, et al. Sigma 1 Receptor is Overexpressed in Hepatocellular Adenoma: Involvement of ERα and HNF1α. Cancers (Basel). 2020;12(8)doi: 10.3390/cancers12082213.
Villemain, L., Prigent, S., Abou-Lovergne, A., Pelletier, L., Chiral, M., Pontoglio, M., Foufelle, F., Caruso, S., Pineau, R., Rebouissou, S., Chevet, E., Zucman-Rossi, J., & Combettes, L. (2020). Sigma 1 Receptor is Overexpressed in Hepatocellular Adenoma: Involvement of ERα and HNF1α. Cancers, 12(8), . https://doi.org/10.3390/cancers12082213
Villemain, Laure, et al. "Sigma 1 Receptor is Overexpressed in Hepatocellular Adenoma: Involvement of ERα and HNF1α." Cancers vol. 12,8 (2020). doi: https://doi.org/10.3390/cancers12082213
Villemain L, Prigent S, Abou-Lovergne A, Pelletier L, Chiral M, Pontoglio M, Foufelle F, Caruso S, Pineau R, Rebouissou S, Chevet E, Zucman-Rossi J, Combettes L. Sigma 1 Receptor is Overexpressed in Hepatocellular Adenoma: Involvement of ERα and HNF1α. Cancers (Basel). 2020 Aug 07;12(8). doi: 10.3390/cancers12082213. PMID: 32784704; PMCID: PMC7464972.
Copy Download .nbib Format: NLM
Assessing treatment response after intravesical bacillus Calmette-Guerin induction cycle: are routine bladder biopsies necessary?.

World journal of urology

Calò B, Sanguedolce F, Falagario UG, Chirico M, Fortunato F, Carvalho-Diaz E, Busetto GM, Bettocchi C, Carrieri G, Cormio L.
PMID: 33830306
World J Urol. 2021 Oct;39(10):3815-3821. doi: 10.1007/s00345-021-03690-w. Epub 2021 Apr 08.

PURPOSE: To determine the need for routine bladder biopsies (BBs) in assessing response to the induction cycle of intravesical bacillus Calmette-Guérin (BCG) for high-risk non-muscle-invasive bladder cancer (NMIBC).METHODS: Our prospectively maintained NMIBC database was queried to identify patients with...

Cite
Calò B, Sanguedolce F, Falagario UG, et al. Assessing treatment response after intravesical bacillus Calmette-Guerin induction cycle: are routine bladder biopsies necessary?. World J Urol. 2021;39(10):3815-3821doi: 10.1007/s00345-021-03690-w.
Calò, B., Sanguedolce, F., Falagario, U. G., Chirico, M., Fortunato, F., Carvalho-Diaz, E., Busetto, G. M., Bettocchi, C., Carrieri, G., & Cormio, L. (2021). Assessing treatment response after intravesical bacillus Calmette-Guerin induction cycle: are routine bladder biopsies necessary?. World journal of urology, 39(10), 3815-3821. https://doi.org/10.1007/s00345-021-03690-w
Calò, Beppe, et al. "Assessing treatment response after intravesical bacillus Calmette-Guerin induction cycle: are routine bladder biopsies necessary?." World journal of urology vol. 39,10 (2021): 3815-3821. doi: https://doi.org/10.1007/s00345-021-03690-w
Calò B, Sanguedolce F, Falagario UG, Chirico M, Fortunato F, Carvalho-Diaz E, Busetto GM, Bettocchi C, Carrieri G, Cormio L. Assessing treatment response after intravesical bacillus Calmette-Guerin induction cycle: are routine bladder biopsies necessary?. World J Urol. 2021 Oct;39(10):3815-3821. doi: 10.1007/s00345-021-03690-w. Epub 2021 Apr 08. PMID: 33830306; PMCID: PMC8519823.
Copy Download .nbib Format: NLM
Influence of Thickness on the Magnetic and Magnetotransport Properties of Epitaxial La.

Nanomaterials (Basel, Switzerland)

Greculeasa SG, Stanciu AE, Leca A, Kuncser A, Hrib L, Chirila C, Pasuk I, Kuncser V.
PMID: 34947736
Nanomaterials (Basel). 2021 Dec 14;11(12). doi: 10.3390/nano11123389.

Epitaxial La

Cite
Greculeasa SG, Stanciu AE, Leca A, et al. Influence of Thickness on the Magnetic and Magnetotransport Properties of Epitaxial La. Nanomaterials (Basel). 2021;11(12)doi: 10.3390/nano11123389.
Greculeasa, S. G., Stanciu, A. E., Leca, A., Kuncser, A., Hrib, L., Chirila, C., Pasuk, I., & Kuncser, V. (2021). Influence of Thickness on the Magnetic and Magnetotransport Properties of Epitaxial La. Nanomaterials (Basel, Switzerland), 11(12), . https://doi.org/10.3390/nano11123389
Greculeasa, Simona Gabriela, et al. "Influence of Thickness on the Magnetic and Magnetotransport Properties of Epitaxial La." Nanomaterials (Basel, Switzerland) vol. 11,12 (2021). doi: https://doi.org/10.3390/nano11123389
Greculeasa SG, Stanciu AE, Leca A, Kuncser A, Hrib L, Chirila C, Pasuk I, Kuncser V. Influence of Thickness on the Magnetic and Magnetotransport Properties of Epitaxial La. Nanomaterials (Basel). 2021 Dec 14;11(12). doi: 10.3390/nano11123389. PMID: 34947736.
Copy Download .nbib Format: NLM
Romanian Guidelines for Nonpharmacological Therapy of IBS.

Journal of gastrointestinal and liver diseases : JGLD

Dumitrascu DL, Baban A, Bancila I, Barboi O, Bataga S, Chira A, Chirila I, Cijevschi Prelipcean C, Ciobanu L, Cozma-Petrut A, David L, Diculescu M, Dobru D, Dimitriu A, Dumitru E, Fadgyas-Stanculete M, Gheorghe C, Gilca-Blanariu GE, Goldis A, Grad S, Macarie M, Marica-Sabo C, Miere D, Nedelcu L, Negovan A, Pojoga C, Pop AV, Popa SL, Porr PJ, Rusu F, Seicean A, Sporea I, Stroie T, Blaga-Surdea T, Tocia C, Trifan A, Brisc C, Drug V.
PMID: 33951120
J Gastrointestin Liver Dis. 2021 Jun 18;30(2):291-306. doi: 10.15403/jgld-3581.

BACKGROUND AND AIMS: The nonpharmacological therapy in irritable bowel syndrome (IBS) is expanding rapidly. Practitioners and medical educators need to be aware of progress and changes in knowledge of this topic. The Romanian Society of Neurogastroenterology aimed to create...

Cite
Dumitrascu DL, Baban A, Bancila I, et al. Romanian Guidelines for Nonpharmacological Therapy of IBS. J Gastrointestin Liver Dis. 2021;30(2):291-306doi: 10.15403/jgld-3581.
Dumitrascu, D. L., Baban, A., Bancila, I., Barboi, O., Bataga, S., Chira, A., Chirila, I., Cijevschi Prelipcean, C., Ciobanu, L., Cozma-Petrut, A., David, L., Diculescu, M., Dobru, D., Dimitriu, A., Dumitru, E., Fadgyas-Stanculete, M., Gheorghe, C., Gilca-Blanariu, G. E., Goldis, A., Grad, S., Macarie, M., Marica-Sabo, C., Miere, D., Nedelcu, L., Negovan, A., Pojoga, C., Pop, A. V., Popa, S. L., Porr, P. J., Rusu, F., Seicean, A., Sporea, I., Stroie, T., Blaga-Surdea, T., Tocia, C., Trifan, A., Brisc, C., & Drug, V. (2021). Romanian Guidelines for Nonpharmacological Therapy of IBS. Journal of gastrointestinal and liver diseases : JGLD, 30(2), 291-306. https://doi.org/10.15403/jgld-3581
Dumitrascu, Dan L, et al. "Romanian Guidelines for Nonpharmacological Therapy of IBS." Journal of gastrointestinal and liver diseases : JGLD vol. 30,2 (2021): 291-306. doi: https://doi.org/10.15403/jgld-3581
Dumitrascu DL, Baban A, Bancila I, Barboi O, Bataga S, Chira A, Chirila I, Cijevschi Prelipcean C, Ciobanu L, Cozma-Petrut A, David L, Diculescu M, Dobru D, Dimitriu A, Dumitru E, Fadgyas-Stanculete M, Gheorghe C, Gilca-Blanariu GE, Goldis A, Grad S, Macarie M, Marica-Sabo C, Miere D, Nedelcu L, Negovan A, Pojoga C, Pop AV, Popa SL, Porr PJ, Rusu F, Seicean A, Sporea I, Stroie T, Blaga-Surdea T, Tocia C, Trifan A, Brisc C, Drug V. Romanian Guidelines for Nonpharmacological Therapy of IBS. J Gastrointestin Liver Dis. 2021 Jun 18;30(2):291-306. doi: 10.15403/jgld-3581. PMID: 33951120.
Copy Download .nbib Format: NLM
Transthyretin cardiac amyloidosis.

Medicine and pharmacy reports

Tomoaia R, Beyer R, Manole S, Chirilă A, Dădârlat-Pop A, Minciună IA, Pop D.
PMID: 34527900
Med Pharm Rep. 2021 Aug;94:S11-S14. doi: 10.15386/mpr-2219. Epub 2021 Aug 10.

Transthyretin amyloid cardiomyopathy (ATTR-CM) may be an under recognized cause of heart failure (HF). TTR amyloidosis can be inherited, caused by variants in the TTR gene (ATTRv) or by deposition of wild-type TTR protein (ATTRwt), leading to high mortality...

Cite
Tomoaia R, Beyer R, Manole S, et al. Transthyretin cardiac amyloidosis. Med Pharm Rep. 2021;94:S11-S14doi: 10.15386/mpr-2219.
Tomoaia, R., Beyer, R., Manole, S., Chirilă, A., Dădârlat-Pop, A., Minciună, I. A., & Pop, D. (2021). Transthyretin cardiac amyloidosis. Medicine and pharmacy reports, 94S11-S14. https://doi.org/10.15386/mpr-2219
Tomoaia, Raluca, et al. "Transthyretin cardiac amyloidosis." Medicine and pharmacy reports vol. 94 (2021): S11-S14. doi: https://doi.org/10.15386/mpr-2219
Tomoaia R, Beyer R, Manole S, Chirilă A, Dădârlat-Pop A, Minciună IA, Pop D. Transthyretin cardiac amyloidosis. Med Pharm Rep. 2021 Aug;94:S11-S14. doi: 10.15386/mpr-2219. Epub 2021 Aug 10. PMID: 34527900; PMCID: PMC8411828.
Copy Download .nbib Format: NLM
Effect of inulin in the treatment of irritable bowel syndrome with constipation (Review).

Experimental and therapeutic medicine

Bărboi OB, Ciortescu I, Chirilă I, Anton C, Drug V.
PMID: 33101475
Exp Ther Med. 2020 Dec;20(6):185. doi: 10.3892/etm.2020.9315. Epub 2020 Oct 13.

At present, irritable bowel syndrome (IBS) is a common medical problem all over the world that implies considerable social burden and high costs. Considering the different pathophysiological pathways, unitary management for IBS is not possible. Of the therapeutic approaches...

Cite
Bărboi OB, Ciortescu I, Chirilă I, et al. Effect of inulin in the treatment of irritable bowel syndrome with constipation (Review). Exp Ther Med. 2020;20(6):185doi: 10.3892/etm.2020.9315.
Bărboi, O. B., Ciortescu, I., Chirilă, I., Anton, C., & Drug, V. (2020). Effect of inulin in the treatment of irritable bowel syndrome with constipation (Review). Experimental and therapeutic medicine, 20(6), 185. https://doi.org/10.3892/etm.2020.9315
Bărboi, Oana-Bogdana, et al. "Effect of inulin in the treatment of irritable bowel syndrome with constipation (Review)." Experimental and therapeutic medicine vol. 20,6 (2020): 185. doi: https://doi.org/10.3892/etm.2020.9315
Bărboi OB, Ciortescu I, Chirilă I, Anton C, Drug V. Effect of inulin in the treatment of irritable bowel syndrome with constipation (Review). Exp Ther Med. 2020 Dec;20(6):185. doi: 10.3892/etm.2020.9315. Epub 2020 Oct 13. PMID: 33101475; PMCID: PMC7579772.
Copy Download .nbib Format: NLM
Efficacy of Natural Formulations in Bovine Mastitis Pathology: Alternative Solution to Antibiotic Treatment.

Journal of veterinary research

Pașca C, Mărghitaș LA, Dezmirean DS, Matei IA, Bonta V, Pașca I, Chirilă F, Cîmpean A, Iosif Fiț N.
PMID: 33367141
J Vet Res. 2020 Oct 20;64(4):523-529. doi: 10.2478/jvetres-2020-0067. eCollection 2020 Dec.

INTRODUCTION: Bovine mastitis is an inflammatory disease of the udder that causes important economic losses in the animal breeding and dairy product industries. Nowadays, the conventional livestock antibiotic treatments are slowly being replaced by alternative treatments. In this context,...

Cite
Pașca C, Mărghitaș LA, Dezmirean DS, et al. Efficacy of Natural Formulations in Bovine Mastitis Pathology: Alternative Solution to Antibiotic Treatment. J Vet Res. 2020;64(4):523-529doi: 10.2478/jvetres-2020-0067.
Pașca, C., Mărghitaș, L. A., Dezmirean, D. S., Matei, I. A., Bonta, V., Pașca, I., Chirilă, F., Cîmpean, A., & Iosif Fiț, N. (2020). Efficacy of Natural Formulations in Bovine Mastitis Pathology: Alternative Solution to Antibiotic Treatment. Journal of veterinary research, 64(4), 523-529. https://doi.org/10.2478/jvetres-2020-0067
Pașca, Claudia, et al. "Efficacy of Natural Formulations in Bovine Mastitis Pathology: Alternative Solution to Antibiotic Treatment." Journal of veterinary research vol. 64,4 (2020): 523-529. doi: https://doi.org/10.2478/jvetres-2020-0067
Pașca C, Mărghitaș LA, Dezmirean DS, Matei IA, Bonta V, Pașca I, Chirilă F, Cîmpean A, Iosif Fiț N. Efficacy of Natural Formulations in Bovine Mastitis Pathology: Alternative Solution to Antibiotic Treatment. J Vet Res. 2020 Oct 20;64(4):523-529. doi: 10.2478/jvetres-2020-0067. eCollection 2020 Dec. PMID: 33367141; PMCID: PMC7734678.
Copy Download .nbib Format: NLM
[The combination treatment of arterial hypertension].

Viata medicala; revista de informare profesionala si stiintifica a cadrelor medii sanitare

Menek G, Gegö K, Tréfás I, Nagy I, Chiriac M.
PMID: 6812280
Viata Med Rev Inf Prof Stiint Cadrelor Medii Sanit. 1982 Jan;30(1):5-6.

No abstract available.

Cite
Menek G, Gegö K, Tréfás I, et al. Tratamentul complex al hipertensiunii arteriale. [The combination treatment of arterial hypertension]. Viata Med Rev Inf Prof Stiint Cadrelor Medii Sanit. 1982;30(1):5-6
Menek, G., Gegö, K., Tréfás, I., Nagy, I., & Chiriac, M. (1982). Tratamentul complex al hipertensiunii arteriale. [The combination treatment of arterial hypertension]. Viata medicala; revista de informare profesionala si stiintifica a cadrelor medii sanitare, 30(1), 5-6.
Menek, G, et al. "Tratamentul complex al hipertensiunii arteriale." [The combination treatment of arterial hypertension]. Viata medicala; revista de informare profesionala si stiintifica a cadrelor medii sanitare vol. 30,1 (1982): 5-6.
Menek G, Gegö K, Tréfás I, Nagy I, Chiriac M. Tratamentul complex al hipertensiunii arteriale. [The combination treatment of arterial hypertension]. Viata Med Rev Inf Prof Stiint Cadrelor Medii Sanit. 1982 Jan;30(1):5-6. Romanian. PMID: 6812280.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 110 entries